25 C
Delhi
Monday, September 1, 2025

Alembic Pharma receives USFDA approval for Fulvestrant Injection

Date:

Share post:

Donate-GC-Razorpay

Mumbai: Pharma Major, Alembic Pharma on Monday said it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Prefilled Syringe.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Faslodex Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP.

Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of breast cancer. Refer to our label for full indication.

Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US$71 million for twelve months ending September 2022, according to IQVIA.

Related articles

Self-reliance in Defence is not merely an option, but a condition for survival & progress: Rajnath Singh

New Delhi: Defence Minister Rajnath Singh said that in today’s era of terrorism, pandemics and regional conflicts, self-reliance...

Putin advocates reforms in UN, IMF to reflect modern realities

Moscow/Beijing: Russian President Vladmir Putin, ahead of the upcoming SCO summit in the Chinese city of Tianjin, lauded...

India’s GDP surges 7.8 pc in Q1 FY 26, led by services and manufacturing

New Delhi: India’s economy sprinted ahead in the first quarter of FY 2025-26, with real Gross Domestic Product...

India crush Nepal 5-0 to clinch SAFF U17 Women’s Championship 2025 title

New Delhi/Thimphu: India’s dominance in South Asian football continued as the U 17 women’s team thrashed Nepal 5-0...